La revascularización incompleta no tiene el mismo significado en todos los pacientes

Aspiration Thrombectomy in Acute Coronary Syndrome: Is the Japanese Perspective a Strategy to Emulate?

Aspiration thrombectomy (AT) in patients with high thrombotic burden could pathophysiologically reduce thrombus burden, decrease distal embolization, reduce no-reflow phenomenon, and improve microvascular perfusion. However, its usefulness has not been shown in the large, randomized trials (TASTE and TOTAL) that compared routine use of AT in primary angioplasty in patients with ST-segment elevation acute coronary<a href="https://solaci.org/en/2022/08/26/aspiration-thrombectomy-in-acute-coronary-syndrome-is-the-japanese-perspective-a-strategy-to-emulate/" title="Read more" >...</a>

¿Es frecuente el uso de IVUS para guiar la ATC?

Optimization by IVUS after FFR Guided PCI: Are There Clinical Benefits for Patients?

Percutaneous coronary interventions have improved during the last decade with 15% rate of target vessel failure (TVF) at 5 years according to the latest reports. We are already familiar with the benefits of functional assessment of lesions with FFR and its clinical outcomes.  Additionally, low post PCI FFR values (FFR ≤ 0.83-≤0.91) have been associated<a href="https://solaci.org/en/2022/08/24/optimization-by-ivus-after-ffr-guided-pci-are-there-clinical-benefits-for-patients/" title="Read more" >...</a>

La endarterectomía precoz parece superior a la angioplastia carotidea en pacientes sintomáticos

Clinical Results of IVUS-Guided Drug-Eluting Stent Implantation in Femoropopliteal Disease

Endovascular treatment of femoropopliteal lesions has become the first-line treatment due to the development of devices that decrease the restenosis rate. Recently, the IMPERIAL study showed greater patency at 1 year and greater freedom from clinically guided revascularization at 2 years in favor of the ELUVIA stent (paclitaxel-eluting fluoropolymer, FP-DES) compared with the ZILVER PTX<a href="https://solaci.org/en/2022/08/23/clinical-results-of-ivus-guided-drug-eluting-stent-implantation-in-femoropopliteal-disease/" title="Read more" >...</a>

El ticagrelor muestra beneficios en la función microvascular coronaria luego de un IAMSEST

Ticagrelor Monotherapy: Valid after 12 Months?

Recent studies on antiplatelet antiaggregation support the use of short dual antiaggregation therapy (DAPT), even in unforeseen scenarios, such as complex PCI.  On the contrary, in patients with high ischemic risk, there is still evidence in favor of prolonged antiaggregation, mainly through the DAPT study, which showed lower risk of major ischemic events with DAPT<a href="https://solaci.org/en/2022/08/12/ticagrelor-monotherapy-valid-after-12-months/" title="Read more" >...</a>

The Best of the SOLACI-SOCIME 2022 Main Arena: Day 3

Lecture by Dr. Hector García García – LM-PCI: IVUS and FFR/IFR? Dr. Hector García delivered an excellent presentation on whether we should use intravascular ultrasound (IVUS) or fractional flow reserve (FFR)/instantaneous wave-free ratio (iFR) in the left main coronary artery (LMCA) to consider severe obstruction, since there is significant interobserver variability with angiography. Although the<a href="https://solaci.org/en/2022/08/11/the-best-of-the-solaci-socime-2022-main-arena-day-3/" title="Read more" >...</a>

The Best of the SOLACI-SOCIME 2022 Main Arena: PCI by Radial Access

Angioplasty by transradial access was discussed during a session on Day 2. We were pleased to participate in a conference by Dr. Shigeru Saito on distal radial access.  Currently, complications associated with transfemoral access are well-established, so transradial access is suggested as the initial strategy in several guidelines of various associations.  However, Dr. Saito shared<a href="https://solaci.org/en/2022/08/10/the-best-of-the-solaci-socime-2022-main-arena-pci-by-radial-access/" title="Read more" >...</a>

Leak periprotésico en cierre de orejuela, algo más que un valor para tener en cuenta

Peridevice Leak in Left Atrial Appendage Closure: more than one value to take into account

According to several registries, incomplete left atrial appendage (LAA) closure has been observed in up to 30% of cases after device implantation. The main cause of this complication is a mismatch between closure device and LAA ostium. The latter is elliptical in shape and varies in length, while the Watchman LAA closure device is round<a href="https://solaci.org/en/2022/07/29/peridevice-leak-in-left-atrial-appendage-closure-more-than-one-value-to-take-into-account/" title="Read more" >...</a>

stent-liberador-drogas-sirolimus-everolimus

Thin vs. Ultrathin Stents: 1-Year Clinical Results After IVUS/OCT-Guided Implantation

Second generation drug-eluting stents have lower frequency of thrombotic complications and in-stent restenosis. While clinical results have significantly improved, having a 2-3% annual rate of these complications within the first year after angioplasty is still worrisome. This resulted in the development of stents with struts <70 µm (ultrathin), with bioresorbable polymer and abluminal cover. Stents<a href="https://solaci.org/en/2022/07/20/thin-vs-ultrathin-stents-1-year-clinical-results-after-ivus-oct-guided-implantation/" title="Read more" >...</a>

Resultado a 3 años luego de ATC con técnica de 2- stents vs Provisional stent por bifurcaciones complejas

Three-Year Outcomes after CTA with 2-Stent Technique Vs. Provisional Stenting for Complex Bifurcation Lesions

The prevalence of coronary lesions with bifurcation involvement is about 20% in patients undergoing coronary angiography (CTA). While provisional stenting is overall the most accepted technique, the 2018 myocardial revascularization guidelines recommend the 2-stent technique for complex bifurcation lesions, defined as side branch with lesion >5mm, distal reference diameter of the side branch ≥2.75, or<a href="https://solaci.org/en/2022/07/13/three-year-outcomes-after-cta-with-2-stent-technique-vs-provisional-stenting-for-complex-bifurcation-lesions/" title="Read more" >...</a>

Doble antiagregación en TAVI, simple es mejor?

High Risk of Bleeding after PCI: More Evidence for Short DAPT

Dual antiaggregation therapy (DAPT) with ASA and P2Y12 during 6 to 12 months is the indicated strategy after DES stenting to reduce ischemic events. However, in patients with elevated risk of bleeding (HBR) guideline and expert recommendations is 1-6 months, since there is plenty of evidence in favor, except for a randomized study, the MASTER<a href="https://solaci.org/en/2022/07/06/high-risk-of-bleeding-after-pci-more-evidence-for-short-dapt/" title="Read more" >...</a>

thrombosis